What type of study is this?

This is a RCT study (also classified as: Phase 2).

Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (S EASI DE CHINA): initial two-week dosing, followed by two-week or four-week dosing

View Full Paper

Ask AI

Bookmark

Rademikibart Q2W led to a 29.0% improvement in skin lesions at Week 16, compared to 5.9% for placebo.
Stage 1 showed significant gains in EASI-75 for rademikibart Q2W at 58.6% vs 22.6% for placebo at Week 16.
Observational analysis across 330 patients with moderate-to-severe AD monitored over 52 weeks shows continued efficacy.
No serious treatment-related adverse events were noted, supporting the safety profile of rademikibart therapy.

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates rademikibart efficacy in adults with atopic dermatitis, indicating significant improvements in skin lesions and pruritus.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates rademikibart efficacy in adults with atopic dermatitis, indicating significant improvements in skin lesions and pruritus.